Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-711-1 | CAS number: 148-24-3
Endpoint summary
Administrative data
Description of key information
Skin sensitisation, patch test (key, RL2): sensitising
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
Sensitisation
No skin sensitisation studies in animals are available to evaluate the skin sensitizing properties of quinolin-8-ol (CAS 148-24-3). However, relevant information in humans is available that allow a final assessment of skin sensitising properties induced by quinolin-8-ol.
Skin sensitising properties of quinolin-8-ol (CAS 148-24-3) were determined in a human Patch test by topical application of the test substance (Pevny and Schellenberger, 1971). Three Patch tests were conducted with 100 or 127 patients. A positive sensitisation response was observed in all three tests. The indices of sensitivity (percentage of positive responses) were 4.7%, 8% and 6% in all 3 studies, respectively. Thus, quinolin-8-ol is considered to be an allergen in humans.
Furthermore, patients showed signs of contact allergy to quinolin-8-ol and to 8-hydroxyquinoline sulphate during dermatological therapies. In detail, in an epidermal test series for the determination of contact eczema caused by drugs within a period of six years, hypersensitivity to 8-hydroxyquinoline was observed in 3/450 patients indicating that quinolin-8-ol is a weak contact allergen. Furthermore, 8-hydroxyquinoline sulphate showed a positive response in one subject at concentrations above 0.01% and was considered as strong sensitiser (as cited in RAC opinion (Rothe, 1978; Metzner, 1987).
Overall conclusion
Based on the available data, human data provide evidence that quinolin-8-ol exhibits skin sensitisng properties by skin contact in a substantial number of people. Thus, quinolin-8-ol is considered as skin sensitizer. Due to limited information, sub-categorisation according to CLP criteria is not possible.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available data on skin sensitization induced by quinolin-8-ol (CAS 148 -24 -3) meet the criteria for classification as Skin sens 1, H317 according to Regulation (EC) 1272/2008. Due to limited information, sub-categorisation according to CLP criteria is not possible.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
